Literature DB >> 21931583

Rhabdomyolysis caused by an interaction of simvastatin and fusidic acid.

Roselle Herring1, Gordon Caldwell, Stuart Wade.   

Abstract

A case of severe rhabdomyolysis caused by an interaction between fusidic acid and simvastatin is described. Fusidic acid significantly reduces the excretion of simvastatin resulting in increased plasma levels thereby increasing the side effect profile. Simvastatin treatment should be temporarily withheld during treatment with fusidic acid.

Entities:  

Year:  2009        PMID： 21931583      PMCID： PMC3027476          DOI： 10.1136/bcr.03.2009.1722

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  11 in total

1.  Interaction between ritonavir and statins.

Authors:  Peter J Piliero
Journal:  Am J Med       Date:  2002-04-15       Impact factor: 4.965

2.  Acute rhabdomyolysis after atorvastatin and fusidic acid therapy.

Authors:  C Wenisch; R Krause; P Fladerer; I El Menjawi; E Pohanka
Journal:  Am J Med       Date:  2000-07       Impact factor: 4.965

3.  Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin.

Authors:  Sam L S Yuen; Bruce McGarity
Journal:  Med J Aust       Date:  2003-08-04       Impact factor: 7.738

4.  Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy.

Authors:  Benjamin D Mackie; Sameer Satija; Christine Nell; Joseph Miller; Laurence S Sperling
Journal:  Am J Cardiol       Date:  2006-11-27       Impact factor: 2.778

5.  Presumed interaction of fusidic acid with simvastatin.

Authors:  A J Burtenshaw; G Sellors; R Downing
Journal:  Anaesthesia       Date:  2008-06       Impact factor: 6.955

Review 6.  Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors:  David Williams; John Feely
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity.

Authors:  F Russell Westwood; Alison Bigley; Kevin Randall; Alan M Marsden; Robert C Scott
Journal:  Toxicol Pathol       Date:  2005       Impact factor: 1.902

8.  The MRC/BHF Heart Protection Study: preliminary results.

Authors:  Rory Collins; Richard Peto; Jane Armitage
Journal:  Int J Clin Pract       Date:  2002 Jan-Feb       Impact factor: 2.503

9.  Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.

Authors:  P J Gruer; J M Vega; M F Mercuri; M R Dobrinska; J A Tobert
Journal:  Am J Cardiol       Date:  1999-10-01       Impact factor: 2.778

10.  Rhabdomyolysis with atorvastatin and fusidic acid.

Authors:  C O'Mahony; V L Campbell; M S Al-Khayatt; D J Brull
Journal:  Postgrad Med J       Date:  2008-06       Impact factor: 2.401
View more
  3 in total

1.  Rhabdomyolysis with simvastatin.

Authors:  Brijesh R Patel; Maitrayee Choudhury
Journal:  BMJ Case Rep       Date:  2011-01-11

2.  Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.

Authors:  Anshul Gupta; Jennifer J Harris; Jianrong Lin; James P Bulgarelli; Bruce K Birmingham; Scott W Grimm
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 3.  Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions.

Authors:  Thomas Deljehier; Antoine Pariente; Ghada Miremont-Salamé; Françoise Haramburu; Linh Nguyen; Sébastien Rubin; Claire Rigothier; Hélène Théophile
Journal:  Br J Clin Pharmacol       Date:  2018-02-26       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.